COVID-19 Results Briefing

The European Region

September 15, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in the European Region. The model was run on September 14, 2021, with data through September 13, 2021.

Delta variant surges continue to unfold in many countries in Central and Eastern Europe, as well as in Sweden, Germany, Austria, and Scotland. In some parts of Eastern Europe, all of Central Asia, Portugal, Spain, France, Italy, and Denmark, transmission continues to decline. Delta surges have started to show up in Hungary and Slovakia and are likely to appear soon in Poland and Czechia. The unusual double Delta surge seen in Scotland may be present in Wales, but it has not spread to other countries that have had sustained declines after a Delta peak. Given the strong west to east declining gradient in vaccination rates, the reason for the peaks in the western part of the region is more linked to high vaccination rates and moderate past infection rates. In Russia and Central Asia, however, the declines are more likely linked to very high rates of past infection and low to modest vaccination rates. We estimate that 53% of the region's population is currently immune to the Delta variant and this could increase to 67% by January 1. In our reference scenario, we expect current Delta surges, combined with seasonality, to lead to a slow but steady increase in cases and deaths starting in mid-October, with daily deaths reaching well over 3,000 by early December. Given vaccination rates, the expected increase in reported cases is greater, reaching 500,000 by mid-December. These reference forecasts may be optimistic for two critical reasons. First, we do not take into account waning immunity. More and more evidence is emerging from post-vaccination studies in England, the US, and Israel and from the long-term follow-up of the Pfizer and Moderna trials that vaccine-derived immunity wanes for preventing infection. This week, some evidence is also emerging that vaccine-derived immunity for hospitalization and death may also wane, albeit at a slower rate. We plan to revise our model to incorporate this evidence on waning immunity over the next weeks. Second, we do not take into account the potential emergence of a new variant with increased transmissibility or immune escape. Some analysts have raised concern about the Mu variant, but there is not yet any population-level data to suggest this will lead to new surges. Strategies to manage the pandemic include: 1) expanding vaccination coverage by addressing vaccine hesitancy, particularly in the eastern part of the region; 2) promoting behaviors such as seasonal mask use in the at-risk populations to reduce the burden in late fall and winter; 3) consideration of booster shots given the growing evidence on waning immunity, particularly in the at-risk populations; 4) use of mitigation measures to avoid school-based increases in transmission, including mask use, distancing, and vaccination requirements in ages 12 and older; and 5) hospital resource planning for potential high demand for hospitalization when both COVID-19 and influenza coincide in the winter.

Current situation

- Daily infections in the last week decreased to 878,200 per day on average compared to 960,000 the week before (Figure 1). Daily hospital census in the last week (through September 13) remained unchanged at 231,000 per day on average.
- Daily reported cases in the last week increased slightly to 170,100 per day on average compared to 168,600 the week before (Figure 2).
- Reported deaths due to COVID-19 in the last week remained constant at 2,000 per day on average compared to the week before (Figure 3).
- Excess deaths due to COVID-19 in the last week decreased to 9,500 per day on average compared to 9,800 the week before (Figure 3). This makes COVID-19 the number 1 cause of death in the European Region this week (Table 1). Estimated excess daily deaths due to COVID-19 in the past week were 4.6 times larger than the reported number of deaths.
- The daily reported COVID-19 death rate is greater than 4 per million in Armenia, Bosnia and Herzegovina, Bulgaria, Georgia, Kazakhstan, Lithuania, Montenegro, North Macedonia, and the Russian Federation (Figure 4).
- The daily rate of excess deaths due to COVID-19 is greater than 4 per million in 22 countries and some regions in Spain and Italy (Figure 4).
- We estimate that 44% of people in the European Region have been infected as of September 13 (Figure 6).
- Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 28 countries (Figure 7). The southwest and the east of the region have declining transmission, while most of the rest of the region still has increasing transmission.
- The infection-detection rate in the European Region was close to 18% on September 13 (Figure 8).
- Based on the GISAID and various national databases, combined with our variant spread model, we estimate the current prevalence of variants of concern (Figure 9). The Delta variant is the dominant variant in all of the region but has slightly lower prevalence in Turkey than elsewhere.

Trends in drivers of transmission

- Denmark has lifted all mandates except some border restrictions for non-residents (Table 2). Most countries in the region continue to have a mask mandate in place and some form of gathering restrictions.
- Mobility last week was 1% higher than the pre-COVID-19 baseline (Figure 11). Mobility was near baseline (within 10%) in 44 countries. Mobility was lower than 30% of baseline in no locations.
- As of September 13, in the COVID-19 Trends and Impact Survey, 43% of people self-report that they always wore a mask when leaving their home (Figure 13).

- There were 412 diagnostic tests per 100,000 people on September 13 (Figure 15).
- As of September 13, 15 countries have reached 70% or more of the population who have received at least one vaccine dose, and eight countries have reached 70% or more of the population who are fully vaccinated (Figure 17). The marked west to east gradient in vaccination remains.
- In the European Region, 65.7% of adults say they would accept or would probably accept a vaccine for COVID-19. The proportion of the population open to receiving a COVID-19 vaccine ranges from 34% in the Republic of Moldova to 87% in Portugal (Figure 19).
- In our current reference scenario, we expect that 522 million people will be vaccinated with at least one dose by January 1 (Figure 20). We expect that 53% of the population of the region will be fully vaccinated by January 1, 2022.
- Based on the estimate of the population that have been infected with COVID-19 and vaccinated to date, combined with assumptions on protection against infection with the Delta variant provided by either natural infection, vaccination, or both, we estimate that 53% of the region is immune to the Delta variant. In our current reference scenario, we expect that by January 1, 67% of people will be immune to the Delta variant (Figure 21). These two calculations do not take into account waning of natural or vaccine-derived immunity.

Projections

- In our **reference scenario**, which represents what we think is most likely to happen, our model projects 1,622,000 cumulative **reported** deaths due to COVID-19 on January 1. This represents 293,000 additional deaths from September 13 to January 1. Daily reported deaths will rise to 3,400 by mid-December (Figure 22).
- Under our **reference scenario**, our model projects 4,396,000 cumulative **excess** deaths due to COVID-19 on January 1. This represents 778,000 additional deaths from September 13 to January 1 (Figure 22).
- If **universal mask coverage (95%)** were attained in the next week, our model projects 158,000 fewer cumulative reported deaths compared to the reference scenario on January 1.
- Under our **worse scenario**, our model projects 1,868,000 cumulative reported deaths on January 1, an additional 246,000 deaths compared to our reference scenario. Daily reported deaths in the **worse scenario** will rise to 8,040 by November 30, 2021 (Figure 22).
- Daily infections in the **reference scenario** initially decline to a low in early October near 750,000 and then increase again to over 1.0 million by mid-December (Figure 23). Daily infections in the **worse scenario** will rise to 2.5 million by mid-November (Figure 23).

- Daily cases in the **reference scenario** will rise to over 500,000 by late December (Figure 24). Daily cases in the **worse scenario** will rise to 1.2 million by late November (Figure 24).
- Daily hospital census in the **reference scenario** will rise to 325,000 by December 30, 2021 (Figure 25). Daily hospital census in the **worse scenario** will rise to over 750,000 by November 30, 2021 (Figure 25).
- Figure 26 compares our reference scenario forecasts to other publicly archived models. The MIT Delphi model forecasts are markedly different than the other models. MIT Delphi is predicting nearly half a million deaths in Romania in the next three months. The remaining models have similar forecasts until late October. From that point onward, the Imperial forecasts have declining numbers of deaths and the other models have increasing deaths.
- At some point from September through January 1, 27 countries in the region will have high or extreme stress on hospital beds (Figure 27). At some point from September through January 1, 47 countries in the region will have high or extreme stress on intensive care unit (ICU) capacity (Figure 28).

Model updates

No model updates

Figure 1. Daily COVID-19 hospital census and infections



Figure 2. Reported daily COVID-19 cases, moving average



Table 1. Ranking of excess deaths due to COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

Cause name	Weekly deaths	Ranking
COVID-19	66,427	1
Ischemic heart disease	44,253	2
Stroke	22,622	3
Tracheal, bronchus, and lung cancer	8,918	4
Alzheimer's disease and other dementias	8,022	5
Chronic obstructive pulmonary disease	6,719	6
Colon and rectum cancer	5,881	7
Lower respiratory infections	5,254	8
Cirrhosis and other chronic liver diseases	4,290	9
Hypertensive heart disease	3,949	10

Figure 3. Smoothed trend estimate of reported daily COVID-19 deaths (blue) and excess daily deaths due to COVID-19 (orange)



Figure 4. Daily COVID-19 death rate per 1 million on September 13, 2021

A. Daily reported COVID-19 death rate per 1 million



B. Daily excess COVID-19 death rate per 1 million



Figure 5. Cumulative COVID-19 deaths per 100,000 on September 13, 2021

A. Reported cumulative COVID-19 deaths per 100,000



B. Excess cumulative COVID-19 deaths per 100,000



Figure 6. Estimated percent of the population infected with COVID-19 on September 13, 2021



Figure 7. Mean effective R on September 2, 2021. Effective R less than 1 means that transmission should decline, all other things being held the same. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past.



Figure 8. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model. Due to measurement errors in cases and testing rates, the infection-detection rate can exceed 100% at particular points in time.



Figure 9. Estimated percent of circulating SARS-CoV-2 for primary variant families on September 13, 2021

A. Estimated percent Alpha variant

B. Estimated percent Beta variant



C. Estimated percent Delta variant



D. Estimated percent Gamma variant

Figure 10. Infection-fatality rate on September 13, 2021. This is estimated as the ratio of COVID-19 deaths to estimated daily COVID-19 infections.



Critical drivers

Table 2. Current mandate implementation



Figure 11. Trend in mobility as measured through smartphone app use, compared to January 2020 baseline



Figure 12. Mobility level as measured through smartphone app use, compared to January 2020 baseline (percent) on September 13, 2021



Figure 13. Trend in the proportion of the population reporting always wearing a mask when leaving home



Figure 14. Proportion of the population reporting always wearing a mask when leaving home on September 13, 2021



Figure 15. Trend in COVID-19 diagnostic tests per 100,000 people



Figure 16. COVID-19 diagnostic tests per 100,000 people on September 13, 2021



Table 3. Estimates of vaccine efficacy for specific vaccines used in the model at preventing disease and infection. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website.

Vaccine	Efficacy at preventing disease: ancestral and Alpha	Efficacy at preventing infection: ancestral and Alpha	Efficacy at preventing disease: Beta, Delta, & Gamma	Efficacy at preventing infection: Beta, Delta, & Gamma
AstraZeneca	90%	52%	85%	49%
CoronaVac	50%	44%	43%	38%
Covaxin	78%	69%	68%	60%
Johnson & Johnson	86%	72%	60%	56%
Moderna	94%	89%	94%	80%
Novavax	89%	79%	79%	69%
Pfizer/BioNTech	94%	86%	85%	78%
Sinopharm	73%	65%	63%	56%
Sputnik-V	92%	81%	80%	70%
Tianjin CanSino	66%	58%	57%	50%
Other vaccines	75%	66%	65%	57%
Other vaccines (mRNA)	91%	86%	85%	78%

Figure 17. Percent of the population (A) having received at least one dose and (B) fully vaccinated against SARS-CoV-2 by September 13, 2021

A. Percent of the population having received one dose of a COVID-19 vaccine



B. Percent of the population fully vaccinated against SARS-CoV-2



Figure 18. Trend in the estimated proportion of the adult (18+) population that have been vaccinated or would probably or definitely receive the COVID-19 vaccine if available



Figure 19. This figure shows the estimated proportion of the adult (18+) population that has been vaccinated or would probably or definitely receive the COVID-19 vaccine if available



Figure 20. Percent of people who receive at least one dose of a COVID-19 vaccine and those who are fully vaccinated



Figure 21. Percentage of people who are immune to non-escape variants and the percentage of people who are immune to escape variants



Projections and scenarios

We produce three scenarios when projecting COVID-19. The **reference scenario** is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace. Brand- and variant-specific vaccine efficacy is updated using the latest available information from peer-reviewed publications and other reports.
- Future mask use is the mean of mask use over the last 7 days.
- Mobility increases as vaccine coverage increases.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate, and not yet re-imposed social distancing mandates. In this case, the reference scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants Alpha, Beta, Gamma, and Delta continue to spread regionally and globally from locations with sufficient transmission.

The **worse scenario** modifies the reference scenario assumption in four ways:

- 100% of vaccinated individuals stop using masks.
- Mobility increases in all locations to 25% above the pre-pandemic winter baseline, irrespective of vaccine coverage.
- Governments are more reluctant to re-impose social distancing mandates, waiting until the daily death rate reaches 15 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate, and not yet re-imposed social distancing mandates. In this case, the reference scenario assumes that mandates are re-imposed when daily deaths reach 38 per million. In either case, we assume social distancing mandates remain in effect for 6 weeks.
- Variants Alpha, Beta, Gamma, and Delta spread between locations twice as fast when compared with our reference scenario.

The **universal masks scenario** makes all the same assumptions as the reference scenario but assumes all locations reach 95% mask use within 7 days.

Figure 22. Daily COVID-19 deaths until January 01, 2022 for three scenarios

A. Reported daily COVID-19 deaths per 100,000



B. Excess daily COVID-19 deaths per 100,000



Figure 23. Daily COVID-19 infections until January 01, 2022 for three scenarios



Figure 24. Daily COVID-19 reported cases until January 01, 2022 for three scenarios



Figure 25. Daily COVID-19 hospital census until January 01, 2022 for three scenarios



Figure 26. Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology (Delphi), Imperial College London (Imperial), The Los Alamos National Laboratory (LANL), and the SI-KJalpha model from the University of Southern California (SIKJalpha). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.



Figure 27. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered *low stress*, 5-9% is considered *moderate stress*, 10-19% is considered *high stress*, and 20% or greater is considered *extreme stress*.



Figure 28. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered *low stress*, 10-29% is considered *moderate stress*, 30-59% is considered *high stress*, and 60% or greater is considered *extreme stress*.



More information

Data sources:

Mask use and vaccine confidence data are from the The Delphi Group at Carnegie Mellon University and University of Maryland COVID-19 Trends and Impact Surveys, in partnership with Facebook. Mask use data are also from Premise, the Kaiser Family Foundation, and the YouGov COVID-19 Behaviour Tracker survey.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model FAQ page.

A note of thanks:

We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.

To download our most recent results, visit our Data downloads page.

Questions? Requests? Feedback? Please contact us at https://www.healthdata.org/covid/contact-us.